A Single-Center Clinical Study to Evaluate Shenxiong Glucose Injection Combined with Edaravone in the Treatment of Acute Large-Area Cerebral Infarction

Abstract

Objectives. To investigate the clinical efficacy and safety of Shenxiong glucose injection combined with edaravone in the treatment of acute large-area cerebral infarction. Methods. 156 patients with acute large-area cerebral infarction admitted to our hospital from July 2015 to January 2017 were included in the analysis. The patients were randomly divided into experimental (78 cases) and control (78 cases) groups. Patients in the experimental group were given a 30 mg injection of edaravone in 100 ml of 0.9% sodium chloride solution by intravenous drip, twice a day within 30 minutes and a daily 200 ml injection of Shenxiong glucose by intravenous drip. Patients in the control group were given a 30 mg edaravone injection in 100 ml of 0.9% sodium chloride solution by intravenous drip, twice a day, and the drip was completed within 30 minutes. Patients in both groups were treated for 2 weeks. The levels of fibrinogen (FIB), D-dimer, interleukin 6 (IL-6), P-selectin (CD62P), and hypersensitive C-reactive protein (hs-CRP) were evaluated in the two groups of patients. Neurological disability was evaluated using the modified Rankin scale (mRS) and the neurological deficit score (National Institute of Health Stroke Scale, NIHSS). Adverse reactions to the treatments were also recorded. Results. No significant differences in age, gender, medical histories, and blood biochemical indices were observed between the two groups before treatment ( P > 0.05 ). After treatment, the levels of FIB, D-dimer, IL-6, CD62P, and hs-CRP were significantly lower following treatment and compared to the control group ( P < 0.05 ). Also, the mRS and NIHSS scores were significantly lower after treatment and compared with the control group ( P < 0.05 ). The total effective rate of the treatment in the experimental group was significantly higher compared to the control group ( P < 0.05 ). During the treatment period, no obvious adverse reactions were observed in the two groups of patients. Conclusions. In addition to the routine basic treatment of acute large-area cerebral infarction, the addition of Shenxiong glucose injection combined with edaravone injection can improve platelet aggregation and reduce inflammation by affecting P-selectin, D-dimer, and FIB. This treatment approach promotes the recovery of nerve defect function without obvious adverse reactions in patients with acute large-area cerebral infarction.

Significance of Edaravone Combined with Emotion Management Model in Promoting the Recovery Process and Improving Negative Psychology in Patients with Type 2 Diabetes Mellitus Combined with Stroke

“…EDA has a reducing effect on the accumulation of hydrogen peroxide, hydroxyl, and superoxide anion groups in the body and can have an inhibitory effect on unsaturated fatty acid peroxidation and fatty acids (free radical-mediated), thus stabilizing the cell membrane state and promoting the restoration of neural function [22][23][24]. Therefore, in the treatment of CS, EDA can also improve patients' blood glucose function more effectively by inhibiting the oxidative stress response within the body [25]. It was seen that the treatment glycemic function, ADL, and PSQI scores were more excellent in the OG, then suggesting that we could more effectively enhance patients' treatment outcome by implementing an emotional management model during EDA treatment.…”

Exploring the efficacy and molecular mechanism of Danhong injection comprehensively in the treatment of idiopathic pulmonary fibrosis by combining meta-analysis, network pharmacology, and molecular docking methods

“…S miltiorrhiza Bunge, named Danshen in Chinese, has the functions of dredging meridians and relieving pain; Carthami Flos, named Honghua in Chinese, also has the functions of unblocking meridians and relieving pain, [ 6 ] and the combination of the 2 can complement each other, enhance the role of facilitating blood circulation and decreasing blood stasis. At present, as an adjuvant treatment to conventional treatment, Danhong injection has been widely used in cardiovascular disease, [ 7 ] cerebrovascular disease, [ 8 ] respiratory system disease, [ 9 ] and kidney disease [ 10 ] in China, and its curative effect is quite significant. In recent years, Danhong injection has also been widely used in different fibrosis fields.…”